https://www.nasdaq.com/press-release/achieve-life-sciences-announces-completion-of-last-subject-last-follow-up-visit-in
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-%2425-million-loan-facility-from-silicon-valley-bank-to
https://www.nasdaq.com/press-release/achieve-life-sciences-to-host-key-opinion-leader-panel-on-smoking-and-e-cigarette
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-phase-3-orca-2-trial-of-cytisinicline-in-smoking
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-third-quarter-2021-and-provides-update-on
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-participation-in-november-investor-conferences-2021
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-fda-acceptance-of-ind-application-for-cytisiniclines
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-third-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-to-participate-in-upcoming-investor-conferences-2021-09-15
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentation-of-cytisinicline-data-at-the-21st-annual
https://www.nasdaq.com/press-release/achieve-life-sciences-to-participate-in-two-upcoming-investor-conferences-2021-09-09
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-expansion-of-cytisinicline-clinical-operations-team
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-second-quarter-2021-and-provides-corporate
https://www.nasdaq.com/press-release/achieve-announces-two-patents-granted-by-uspto-for-novel-cytisinicline-dosing-and
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-second-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-awarded-grant-from-the-national-institutes-of-health-nih-for
https://www.nasdaq.com/press-release/achieve-announces-completion-of-target-enrollment-of-750-subjects-in-phase-3-orca-2
https://www.nasdaq.com/press-release/achieve-announces-allowance-of-u.s.-patents-for-dosing-and-administration-of
https://www.nasdaq.com/press-release/achieve-life-sciences-to-present-at-ld-micro-invitational-xi-virtual-conference-2021
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-closing-of-public-offering-of-common-stock-and-full
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-pricing-of-%2420-million-underwritten-public-offering
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-proposed-underwritten-public-offering-2021-05-24
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-first-quarter-2021-and-provides-corporate
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-first-quarter-2021-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-inc.-to-host-virtual-non-deal-roadshow-on-tuesday-april-27-2021
https://www.nasdaq.com/press-release/achieve-announces-publication-of-the-orca-1-phase-2b-clinical-trial-of-cytisinicline
https://www.nasdaq.com/press-release/achieve-announces-publication-of-the-rauora-head-to-head-non-inferiority-clinical
https://www.nasdaq.com/press-release/achieve-life-sciences-to-participate-in-m-vest-and-maxim-group-inaugural-emerging
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-appointment-of-dr.-bridget-martell-and-dr.-cindy
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-fourth-quarter-and-year-end-2020-and-provides
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-fourth-quarter-and-year-end-2020-financial-results
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentation-of-data-on-smoker-and-e-cigarette-user
https://www.nasdaq.com/press-release/achieve-life-sciences-to-present-at-the-microcap-rodeo-winter-wonderland-conference
https://www.nasdaq.com/press-release/achieve-life-sciences-to-present-at-h.c.-wainwright-virtual-bioconnect-conference
https://www.nasdaq.com/press-release/achieve-life-sciences-inc.-announces-closing-of-%2417.3-million-underwritten-public
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-pricing-of-%2415-million-public-offering-2020-12-03
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-proposed-public-offering-2020-11-30
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-third-quarter-2020-and-provides-corporate-and
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-third-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-to-host-smoking-cessation-key-opinion-leader-virtual-roundtable
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-to-present-at-the-microcap-best-ideas-conference
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-start-of-phase-3-orca-2-clinical-trial-evaluating
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-appointment-of-john-bencich-to-chief-executive
https://www.nasdaq.com/press-release/achieve-announces-presentation-of-investigator-led-rauora-trial-data-demonstrating
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-results-from-evaluation-of-cytisinicline-cytisine
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentation-of-cytisinicline-data-at-the-20th-annual
https://www.nasdaq.com/press-release/achieve-life-sciences-to-present-at-upcoming-investor-conferences-2020-09-03
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-second-quarter-2020-and-provides-update-on
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-pricing-of-%246.5-million-public-offering-2020-08-04
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-proposed-public-offering-2020-08-03
https://www.nasdaq.com/press-release/achieve-announces-patent-granted-in-the-u.s.-for-novel-analogs-of-cytisinicline-for
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-second-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-pricing-of-%246-million-registered-direct-offering-2020
https://www.nasdaq.com/press-release/achieve-announces-successful-results-from-the-investigator-initiated-rauora-head-to
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-first-quarter-2020-and-provides-update-on
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-first-quarter-2020-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-private-placement-of-%241.9-million-2020-04-30
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-fourth-quarter-and-year-end-2019-and-provides
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentation-of-additional-cytisinicline-analyses-at
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-fourth-quarter-and-year-end-2019-financial-results
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-agreement-with-the-freemind-group-to-assist-in
https://www.nasdaq.com/press-release/achieve-life-sciences-university-of-bristol-and-oracle-corporation-announce-study
https://www.nasdaq.com/press-release/achieve-life-sciences-inc.-announces-closing-of-%2413.8-million-underwritten-public
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-pricing-of-%2412-million-underwritten-public-offering
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-completion-of-meeting-with-the-u.s.-food-drug
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-third-quarter-2019-and-provides-update-on
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-third-quarter-2019-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentation-of-cytisinicline-data-at-society-for
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-completion-of-maximum-tolerated-dose-study-2019-09-30
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-final-phase-2b-orca-1-trial-data-presented-at-society
https://www.nasdaq.com/press-release/achieve-life-sciences-to-host-investor-day-on-september-20th-including-roundtable
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-presentations-at-upcoming-investor-conferences-2019
https://www.nasdaq.com/press-release/achieve-reports-financial-results-for-second-quarter-2019-and-provides-cytisinicline
https://www.nasdaq.com/press-release/achieve-life-sciences-to-announce-second-quarter-2019-financial-results-and-host
https://www.nasdaq.com/press-release/achieve-life-sciences-extends-collaboration-with-the-national-institutes-of-health-to
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-phase-2b-orca-1-trial-data-accepted-for-oral
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-statistically-significant-improvement-quit-rates
https://www.nasdaq.com/press-release/achieve-receives-%244.2-million-exercise-warrants-2019-06-03
https://www.nasdaq.com/press-release/achieve-announces-patent-granted-u.s.-novel-formulation-cytisinicline-2019-05-30
https://www.nasdaq.com/press-release/achieve-life-sciences-announces-last-subject-last-visit-completed-phase-2b-orca-1
